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CLINICAL SCIENCE
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Background: To determine the prevalence of neurocognitive
impairment (NCI) in UK HIV-positive and HIV-negative men who
have sex with men (MSM).
Methods: HIV-positive and HIV-negative participants were recruited to
a cross-sectional study from 2 London clinics and completed computer-
assisted neuropsychological tests and questionnaires of depression,
anxiety, and activities of daily living. Published deﬁnitions of HIV-
associated neurocognitive disorders (HAND) and global deﬁcit scores
were used. Age- and education-adjusted neuropsychological test scores
were directly compared with reference population data.
Results: A total of 248 HIV-positive and 45 HIV-negative MSM
participated. In the HIV-positive group, median time since diagnosis
was 9.4 years, median CD4+ count was 550 cells per cubic millimeter,
and 88% were on antiretroviral therapy. Prevalence of HAND was
21.0% in HIV-positive MSM (13.7% asymptomatic neurocognitive
impairment, 6.5% mild neurocognitive disorder, and 0.8% HIV-
associated dementia). Using a global deﬁcit score threshold of 0.5,
the prevalence of NCI was 31.5% (when averaged over 5 neuropsycho-
logical domains) and 40.3% (over 10 neuropsychological test scores).
These results were not signiﬁcantly different from the HIV-negative
study sample. No consistent pattern of impairment was seen in HIV-
positive patients relative to general male population data (n = 380).
Conclusions: We found a prevalence of HAND and degree of
impairment on neuropsychological testing of HIV-positive MSM
that could represent a normal population distribution. These ﬁndings
suggest that NCI may be overestimated in HIV-positive MSM, and
that the attribution of NCI to HIV infection implied by the term
HAND requires revision.
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INTRODUCTION
The prevalence and implications of HIV-related neuro-
cognitive impairment (NCI) are important but disputed issues
in research and clinical practice. The incidence of HIV-
associated dementia (HAD) has declined dramatically and is
now rarely seen in patients receiving effective antiretroviral
therapy (ART).1–3 However, the prevalence of NCI has been
estimated in some studies of HIV-positive people both on and
off ART at around or above 50%.4–8 In contrast, using
broadly the same deﬁnition but different neuropsychological
(NP) testing methods, only 19% of people in a UK cohort
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were found to have NCI.9 The same prevalence (19%) was
found using another deﬁnition of NCI, the global deﬁcit score
(GDS), in a cohort of HIV-positive US military veterans
receiving ART,10 and there was no impairment in group mean
performance relative to HIV-negative controls.
Updated criteria for HIV-associated neurocognitive dis-
orders (HAND), known as the Frascati criteria, include 3
categories: asymptomatic neurocognitive impairment (ANI),
mild neurocognitive disorder (MND), and HAD.11 Studies re-
porting lower prevalence of NCI in HIV lend weight to concerns
regarding potential overclassiﬁcation when using current deﬁni-
tions of HAND and raise the possibility that the category of ANI
does not reﬂect HIV-related factors but is instead part of a normal
population distribution, insomuch as performance needs to fall
only 1 SD below normal means in 2 of 5 NP domains to meet
the criteria.12 This level of impairment can result in a classiﬁca-
tion of MND or ANI, depending on whether everyday function
is impaired or not, provided HIV seropositivity is conﬁrmed and
major confounders such as delirium, intoxication, and severe
depression are excluded. However, determining everyday func-
tion may be problematic because in most cases it is based on
patients’ self-report, and depressive symptoms themselves have
been shown to predict self-reported functional difﬁculties.13
Given the high rates of depression associated with HIV infec-
tion, this presents a potentially serious confounder.
The wide variation in prevalence estimates and the
difﬁculties in applying current criteria present signiﬁcant chal-
lenges to the interpretation of available data on NCI in HIV-
positive individuals. Our aim was to use a computerized test
battery (CogState) supplemented by standard paper-and-pencil
NP tests to determine the prevalence of NCI in HIV-positive men
who have sex with men (MSM), the largest demographic group
affected by incident and prevalent HIV in Europe,14 deﬁned by
both the Frascati HAND criteria11 and a GDS threshold,15,16 and
to compare the NP scores to general population norms and to
a study control group of HIV-negative MSM.
METHODS
Study Population
The Cognitive Impairment in People with HIV in the
European Region (CIPHER) study is a cross-sectional study of
NCI in HIV outpatients in 4 countries. HIV-positive patients
were consecutively invited to enroll in the Antiretrovirals,
Sexual Transmission Risk and Attitudes (ASTRA) study,17
a questionnaire survey of sexual behavior, in 7 outpatient clinics
in the United Kingdom in 2011–2012. Those enrolled at the
Mortimer Market Centre (MMC) and the Royal Free Hospital
(RFH) (both in London) who consented to have routine clinical
information linked to study data were invited to participate in
CIPHER. Exclusion criteria were age ,18 years, being unable
to understand the questionnaire component of the study because
of language difﬁculties, and being too ill or distressed to com-
plete the assessments. This article refers to the analysis only of
CIPHER participants who were MSM and enrolled in the UK.
Additionally, HIV-negative MSM attending a sexual
health clinic at MMC were recruited in 2011–2012 through
clinician referral, leaﬂets, and advertisement in clinic waiting
rooms. HIV status was conﬁrmed serologically within 1
month before the time of assessment.
Ethical Approval
Ethical approval for the study was obtained from the
National Research Ethics Service (London—Hampstead com-
mittee), reference 11/LO/0077. All study participants gave
written informed consent before commencing the study.
Neuropsychological Testing
CogState is a computerized battery of NP assessments that
has been used in a range of clinical settings.18–23 The CogState
battery was chosen because of its ease of administration, low
testing burden to participants and speed; these are important
factors, given our intention to conduct longitudinal assessments
at a later date. The software has a track record of use in HIV-
positive patients and has been compared with paper-and-pencil
NP tests in this group.9,19,24,25 It performs well in participants
across a range of cultural, economic, linguistic, and social back-
grounds. It is robust against practice effects with performance
considered to become stable after 1 full practice session. We
devised a battery to detect patterns of impairment expected in
HIV, with particular focus on attention, psychomotor speed, and
executive function (see text in Supplemental Digital Content,
http://links.lww.com/QAI/A548, which describes the battery in
more detail). The CogState battery comprised detection (reaction
time), identiﬁcation (choice reaction time), international shop-
ping list, Groton Maze learning, and one-back tasks. In addition,
participants completed 2 tests of verbal ﬂuency and executive
function: the controlled oral word asssociation test (COWAT),
using the letters C, F, and L, and the category ﬂuency test (CFT).
All NP tasks generated a single performance score except for the
one-back task, which deﬁned performance using both accuracy
and speed scores. Performance measures from the NP tasks were
organized into cognitive domains by combining pairs of test
scores as follows: psychomotor speed (detection and identiﬁca-
tion), verbal memory (shopping list learning and recall), execu-
tive function (Groton Maze learning and recall), working
memory maintenance (one-back speed and accuracy), and verbal
ﬂuency (COWAT and CFT).
Functional impairment due to cognitive difﬁculties was
measured using a self-report questionnaire based on an older
tool for measuring function in the elderly26 that has been used
in other observational studies of HIV-related cognitive
impairment5,27,28 (see text in Supplemental Digital Content,
http://links.lww.com/QAI/A548, which describes the ques-
tionnaire in more detail). Declining function was registered
if a participant recorded their current level of functioning as
lower than their best ever in 2 or more of 12 activities of daily
living (ADL) and attributed this decline to cognitive rather
than physical causes. Declining function was graded as mild
(decline in 2–3 ADL) or signiﬁcant (4 or more ADL).
Social, Clinical, and Other Health Data
Participants completed a self-completed conﬁdential
questionnaire developed for the ASTRA study,17 which
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collected information on age, ethnicity, education, smoking,
alcohol (using the CAGE questionnaire),29 recreational drug
use, and sexual behavior. The questionnaire included vali-
dated depression and anxiety symptom inventories (the
PHQ-930 and GAD-7,31 respectively). Viral load, CD4 count,
ART regimen, hepatitis C virus (HCV) status, mental health,
current medication, and other health data were also collected.
Data were corroborated by merging with routinely collected
clinical information. Case notes were reviewed by clinicians
to identify participants who met criteria for serious confound-
ing comorbidities as listed in the Frascati criteria.11
General Population Data
Data were provided by CogState with scores generated by
the computerized tasks from 380 healthy men. These individuals
had been recruited to clinical trials through employment
services, community advertisements, and word of mouth.
Studies providing data for normative databases had been
conducted in Western and Eastern Europe, United States of
America, Southeast Asia, Australia, and New Zealand. All
assessments had been conducted in individual’s ﬁrst language.
Exclusion criteria for individuals contributing data to the norma-
tive database for the CogState tasks included evidence or history
of clinically signiﬁcant neurological, psychiatric, hematological,
renal, endocrine, pulmonary, gastrointestinal, cardiovascular,
hepatic, immunological or allergic disease, and routine use of
sedative medication, analgesic, or other central nervous system
(CNS)-active medications. All data were drawn from individuals
with normal or corrected to normal visual and auditory acuity.
These normative data had been used previously to classify cog-
nitive function in HIV-positive adults18 (also unpublished data
presented by K. Robertson, PhD, et al. at the Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, September
2013). Data were sampled to provide a similar distribution
within strata to the HIV-positive MSM study sample. The gen-
eral male population CogState data were grouped by age (18–
34, 35–50, 51–59 years) and years of education (up to 11, 12–
14, 15–18, $19). The resulting 12 groups were used to deter-
mine normative mean and SD values. Published age-, sex-, and
education-stratiﬁed norms were used for the COWAT and
CFT,32,33 and CogState’s preexisting norms were used for age
$60.
Case Definitions
Raw NP test scores were log-transformed or arcsine root–
transformed where necessary and converted into age- and
education-adjusted Z scores using normative means and SD
(as above). A single Z score was calculated for each of the 5
cognitive domains by averaging pairs of Z scores (see Neuro-
psychological Testing).
For each patient, the Z scores were then used to
determine they met 3 separate deﬁnitions. The ﬁrst was the
Frascati criteria,11 in which HAND was deﬁned by combining
functional assessments with NP scores and other clinical
information. Participants with a Z score of 21 SD or less
in 2 or more domains were classiﬁed as ANI if there was
no functional decline attributed to cognitive difﬁculties, or
MND if there was mild decline. Those scoring 22 SD or less
in 2 or more domains were classiﬁed as ANI if there was no
functional decline, MND if there was mild decline, or HAD if
there was a signiﬁcant decline.
Two GDS were calculated from the average deﬁcit
across all 10 NP test scores and the average deﬁcit across all 5
domains. Deﬁcit was deﬁned for each test by assigning
a score of 0 to Z scores lying above 21.0 and assigning 1
point for each 0.5 decrement in Z score below 21.0. By
assigning normal and above-average Z scores a deﬁcit score
of 0, this system places less weight on tests in the normal or
superior range. In keeping with previous work,15,16 NCI was
deﬁned as GDS $0.5. These case deﬁnitions did not incor-
porate functional status, depression, or other factors.
Statistical Analyses
Overall group characteristics, and the prevalence of NCI
according to the 3 deﬁnitions, were compared between HIV-
positive and HIV-negative study groups, using x2 tests to com-
pare categorical variables and the t test to compare age. Tests for
trend were used to compare ordered categorical variables (grade
of HAND, functional impairment, anxiety, and depression)
between the 2 groups. In sensitivity analyses, comparisons of
the prevalence and grade of NCI were repeated after exclusion
of participants with severe symptoms of depression (deﬁned as
scoring $20 on the PHQ-9), psychosis, delirium, intoxication,
or a previous major CNS condition.
The x2 and Wilcoxon rank-sum tests were used to assess
associations between NCI and covariates including demo-
graphic (age, education, and ethnicity), behavioral (smoking,
alcohol, and drug use), psychological (depression and anxiety
symptoms), and disease-related factors (viral load, CD4, time
since HIV diagnosis, ART status, time on ART, and HCV
coinfection). Multivariable logistic regression was used to
assess the independent effects of these factors found to have
P , 0.15 in univariate analyses. Adjusted odds ratios (ORs)
and 95% conﬁdence intervals (CIs) were estimated.
Additionally, group mean test scores were compared
between HIV-positive MSM and both the general male popula-
tion data supplied by CogState (N = 380) and the group of HIV-
negative MSM recruited to the study, using analysis of covariance
(ANCOVA) with adjustment for age and education.
All reported P values are 2-sided, and a P value
of ,0.05 was considered statistically signiﬁcant. Data were
analyzed using Stata 13 (StataCorp, College Station, TX).
RESULTS
Participant Characteristics
A total of 263 HIV-positive and 49 HIV-negative MSM
were enrolled to CIPHER at 2 UK sites, of whom 251 HIV-
positive and 45 HIV-negative men completed full practice run
and baseline CogState tests. Of these, 3 HIV-positive MSM
had other missing COWAT and CFT scores, leaving 248
HIV-positive and 45 HIV-negative MSM suitable for analy-
sis. Participant characteristics are summarized in Table 1. The
HIV-positive participants were older than the HIV-negative
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group [mean (SD) age of 45.9 (9.1) years compared with 33.4
(7.8); P , 0.001]. Over 80% of both groups were of white
ethnicity and around 60% were university educated. HIV-
positive participants had been diagnosed with HIV for
a median of 9.4 years previously, and around 80% were viro-
logically suppressed on ART and/or had a CD4 count .350
cells per cubic millimeter.
Problem alcohol use (CAGE score of 2 or more) was
apparent in 47 (19.0%) of the HIV-positive and 11 (24.4%) of
the HIV-negative MSM. Recreational drug use in the past 3
months was reported by 126 (54.1%) HIV-positive and 17
(44.7%) HIV-negative participants. Recreational substances
most commonly used (.20% of respondents) were amyl
nitrite (poppers) (29.0%), cannabis (24.0%), and phosphodies-
terase inhibitors (23.3%), followed by cocaine (19.4%),
3,4-methylenedioxy-N-methylamphetamine (ecstasy) (14.7%),
ketamine (11.5%), and g-hydroxybutyric acid (11.1%). Grade
of depressive symptoms was higher in HIV-positive respondents
than in HIV-negative respondents (x2 for trend = 0.0004), and
the proportion graded as moderate depression or above ($10 on
PHQ-9) was 28.9% in HIV-positive compared with 7.9% in
HIV-negative respondents. Moderate-to-severe anxiety symp-
toms were reported by a similar proportion of each group
(20.7% compared with 14.3%; P = 0.38).
Neurocognitive Impairment According to
Standard Criteria
In the HIV-positive sample, the prevalence of HAND
deﬁned by the Frascati criteria was 21.0% (n = 52, 95% CI:
16.1% to 26.6%), graded as ANI in 13.7% (n = 34, 95% CI:
9.7% to 18.6%), MND in 6.5% (n = 16, 95% CI: 3.7% to
10.3%), and HAD in 0.8% (n = 2, 95% CI: 0.1% to 2.9%)
(Table 2). Although the Frascati criteria in the strictest sense
do not apply to HIV-negative individuals, applying the other
elements of the criteria to the HIV-negative sample gave
a prevalence estimate of 28.9% (n = 13, 95% CI: 16.4% to
44.3%), graded as ANI in 24.4% (n = 11, 95% CI: 12.9% to
39.5%), MND in 4.4% (n = 2, 95% CI: 0.5% to 15.1%),
and HAD in none. The difference between the HIV-positive
and HIV-negative groups was not statistically signiﬁcant (P =
0.32, test for trend). Self-reported functional impairment
resulting from cognitive difﬁculties, the sole discriminator
between ANI and MND, was higher in HIV-positive
(29.0%) than in HIV-negative participants (11.1%) (P =
0.007, test for trend), although this did not translate into
a statistically signiﬁcant difference in the proportion of those
meeting HAND criteria who were classiﬁed as symptomatic
(MND or HAD) (P = 0.31).
In a sensitivity analysis, removing those with severe
depressive symptoms reported on the PHQ-9 (n = 17 HIV
positive and n = 2 HIV negative) had little effect on the
prevalence of HAND in either group (Table 2). There were
6 HIV-positive participants with previous AIDS-deﬁning con-
ditions of the CNS that may also be considered confounders
in the causation of NCI: 3 with toxoplasmosis (of whom 1
had MND) and 3 with cryptococcosis (of whom 1 had ANI
and 1 had HAD). Removal of these participants and those
with severe depressive symptoms resulted in there being 31
HIV-positive patients (13.7%) with ANI, 13 (5.8%) with
MND, and 1 (0.4%) with HAD.
Using the GDS algorithm to average 5 cognitive
domains gave a prevalence of NCI of 31.5% (n = 78, 95%
CI: 25.7% to 37.6%) in HIV-positive and 26.7% (n = 12, 95%
CI: 14.6% to 41.9%) in HIV-negative participants; compari-
son between these 2 proportions was not statistically signiﬁ-
cant (P = 0.52). Averaging all 10 test scores gave higher
estimates of 40.3% (n = 100, 95% CI: 34.2% to 46.7%) in
HIV-positive and 42.2% (n = 19, 95% CI: 27.7% to 57.8%) in
HIV-negative participants (again not statistically signiﬁcant,
TABLE 1. Characteristics of the Study Sample, Comparing
HIV-Positive and HIV-Negative Men
HIV-Positive
MSM (N = 248)
HIV-Negative
MSM (N = 45) P
Age, yr, n (%) ,0.001†
18–34 38 (15.3) 30 (66.7)
35–50 141 (56.9) 13 (28.9)
51–75 69 (27.8) 2 (4.4)
White, n (%)* 222 (89.5) 32 (84.2) 0.33
University degree, n (%) 146 (58.9) 29 (64.4) 0.48
Current ART use, n (%) 219 (88.3) NA
Viral load ,50 copies/mL,
n (%)
198 (79.8) NA
CD4 count .350 cells/mm3,
n (%)
211 (85.1) NA
Years since HIV diagnosis,
n (%)
NA
#2 38 (15.3)
3–5 34 (13.7)
6–10 58 (23.4)
$10 118 (47.6)
Problem alcohol use (CAGE
criteria), n (%)
47 (19.0) 11 (24.4) 0.40
Used recreational drugs in
past 3 months, n (%)*
126 (54.1) 17 (44.7) 0.29
HCV antibody positive,
n (%)*
31 (13.1) 0/38 (0) 0.018
Current smoker, n (%)* 65 (28.1) 7 (18.4) 0.21
Depression severity (PHQ-9
scale score), n (%)*
0.0004†
None (0) 49 (20.5) 19 (50.0)
Minimal (1–4) 65 (27.2) 8 (21.1)
Mild (5–9) 56 (23.4) 8 (21.1)
Moderate (10–14) 30 (12.6) 2 (5.3)
Moderately severe (15–19) 22 (9.2) 0
Severe (20–27) 17 (7.1) 1 (2.6)
Anxiety severity (GAD-7
scale score), n (%)*
0.39†
Minimal (0–4) 138 (58.2) 26 (74.3)
Mild (5–9) 50 (21.1) 4 (11.4)
Moderate (10–14) 34 (14.3) 4 (11.4)
Severe (15–21) 15 (6.3) 1 (2.9)
*Missing values are not included in calculations.
†Test for trend.
NA, not applicable.
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P = 0.81). There was little difference to the results after
removal of participants with severe depression symptoms.
Assessment of agreement between the 2 scoring
systems in the HIV-positive sample demonstrated that the
GDS algorithm (averaged over 5 domains) was more sensitive
and/or less speciﬁc than the Frascati criteria: 28 of the 248
(11.3%) participants were classiﬁed as having NCI by the
GDS algorithm but normal by the Frascati criteria, and 2 of
the 248 (0.8%) participants were differentially classiﬁed in
the opposite direction.
Comparison of Neuropsychological Test
Scores Between Groups
Complete CogState test scores were available from 251
HIV-positive participants. To explore which speciﬁc tasks
showed better or worse performance in these patients, individual
test scores were compared with the general male population data
provided by CogState (N = 380) using ANCOVA, adjusted for
age and education (Table 3). Statistically signiﬁcant differences
were found between HIV-positive MSM and general male pop-
ulation in 8 of the 10 scores, although the absolute differences
between the mean scores were small. The direction of difference
favored the HIV-positive sample in 4 tasks (mainly involving
verbal abilities) and favored the general male population in 4
tasks (mainly involving speed and attention).
Individual test scores were also compared between HIV-
positive and HIV-negative (N = 45) study samples, again ad-
justing for age and education using ANCOVA, with additional
adjustment for ﬂuency in English for the verbal memory and
verbal ﬂuency tasks (Table 4). Only 1 test had a statistically
signiﬁcant difference between the 2 groups, the identiﬁcation
task (choice reaction time), which favored HIV-positive partic-
ipants (P = 0.0057). These comparisons should be interpreted
with caution as the group sizes were small (particularly in HIV-
negative MSM group), they relied heavily on statistical
TABLE 2. Estimates of Prevalence of Neurocognitive Impairment in HIV-Positive and HIV-Negative Men
All Participants Excluding Participants With Severe Depressive Symptoms
HIV-Positive MSM
(N = 248)
HIV-Negative
MSM (N = 45) P
HIV-Positive MSM
(N = 231)
HIV-Negative MSM
(N = 44) P
NCI by Frascati criteria, n (%)* 0.32† 0.27†
ANI 34 (13.7) 11 (24.4) 32 (13.9) 11 (25.0)
MND 16 (6.5) 2 (4.4) 14 (6.1) 2 (4.6)
HAD 2 (0.8) 0 2 (0.9) 0
Self-reported functional impairment caused
by cognitive difﬁculties, n (%)
0.007† 0.008†
Mild (2–3 ADL) 38 (15.3) 5 (11.1) 35 (15.2) 4 (9.1)
Signiﬁcant ($4 ADL) 34 (13.7) 0 27 (11.7) 0
GDS for 5 domains, median (IQR) 0.2 (0–0.6) 0.2 (0–0.8) 0.71 0.2 (0–0.6) 0.2 (0–0.9) 0.75
NCI by GDS for 5 domains, n (%) 78 (31.5) 12 (26.7) 0.52 72 (31.2) 12 (27.3) 0.61
GDS for 10 test scores, median (IQR) 0.3 (0.1–0.8) 0.3 (0.1–0.6) 0.77 0.3 (0.1–0.7) 0.3 (0.1–0.8) 0.78
NCI by GDS for 10 test scores, n (%) 100 (40.3) 19 (42.2) 0.81 92 (39.8) 19 (43.2) 0.68
*For the purposes of applying Frascati criteria to HIV-negative participants, HIV status is ignored.
†Test for trend.
IQR, interquartile range; MND, mild neurocognitive disorder.
TABLE 3. Age- and Education-Adjusted Neuropsychological Test Scores in HIV-Positive Male Participants and General Male
Population Data Supplied by CogState
HIV-Positive MSM
(N = 251)*
General Male Population
(N = 380) P Favors Group
Detection latency, mean (SD) log10 ms 2.52 (0.12) 2.49 (0.12) 0.0016 Normal population
Identiﬁcation latency, mean (SD) log10 ms 2.70 (0.10) 2.68 (0.11) 0.0002 Normal population
Groton Maze learning, mean (SD) No. errors 46.3 (15.1) 43.7 (15.4) 0.011 Normal population
Groton Maze recall, mean (SD) No. errors 7.0 (4.0) 6.6 (4.1) 0.21 Normal population
One-back accuracy, mean (SD) arcsine-transformed
proportion correct
1.36 (0.20) 1.30 (0.20) ,0.0001 HIV-positive sample
One-back latency, mean (SD) log10 ms 2.85 (0.13) 2.83 (0.13) 0.0066 Normal population
Shopping list learning, mean (SD) No. correct responses 25.9 (3.9) 25.3 (4.0) 0.029 HIV-positive sample
Shopping list recall, mean (SD) No. correct responses 8.4 (2.3) 8.1 (2.4) 0.101 HIV-positive sample
COWAT, mean (SD) No. valid responses* 40.3 (9.4) 39.1 (9.6) 0.069 HIV-positive sample
CFT, mean (SD) No. valid responses* 21.3 (4.7) 19.9 (4.7) ,0.0001 HIV-positive sample
*Three HIV-positive participants had no data for the COWAT or CFT, and the normal population data were derived from published norms.
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adjustment, and information was limited on the composition of
the general male population sample (N = 380).
Factors Associated With Neurocognitive
Impairment in HIV-Positive Participants
In the HIV-positive group only, factors associated with
any grade of HAND (by Frascati criteria) in the ﬁnal model
were of lower educational attainment (OR = 3.41 vs. univer-
sity or higher degree, 95% CI: 1.73 to 6.70, P , 0.001) and
increasing age (OR = 1.05 per +1 year, 95% CI: 1.01 to 1.08,
P = 0.017). Other social and demographic factors, ART sta-
tus, viral load, HCV status, and current and nadir CD4 count
were not signiﬁcantly associated with HAND. There were no
signiﬁcant associations between self-reported risky sexual
behavior and any of the executive function–based tasks or
global cognitive function. In the HIV-negative group, no fac-
tors were identiﬁed as signiﬁcantly associated with NCI, but
statistical power was limited for these analyses.
DISCUSSION
In this study, we found prevalence of NCI in HIV-
positive participants, all of whom were MSM attending clinics
in London, United Kingdom, of 21% using the Frascati criteria
for HAND, 31% using GDS across 5 cognitive domains, and
40% using GDS across 10 neuropsychological test scores.
Prevalence estimates were very similar for HIV-negative
participants, and direct group comparison with general pop-
ulation data found little overall difference in neuropsycholog-
ical performance. Results were not materially altered after
exclusion of those with severe self-reported symptoms of
depression. This contrasts with studies from the United States,
Switzerland, and France,4–6 which found rates of HAND in
HIV-positive subjects exceeding 50% using similar criteria.
The low prevalence of symptomatic HAND (MND or HAD)
at around 6% after exclusion of those with signiﬁcant
confounding conditions similarly contrasts with previous esti-
mates ranging from 14% to 34%.4–6 Our ﬁndings are more in
keeping with a study of US veterans in which HIV-positive
participants had the same or better cognitive function compared
with HIV-negative controls.10 Variation between studies may
reﬂect differences in population characteristics, the testing
methodology, and/or the scores used as normative data. Even
within our study sample, the choice of case deﬁnition had
a substantial effect on the estimated prevalence of abnormality.
The term “HIV-associated neurocognitive disorder”
contains an implicit attribution of mild neurological impair-
ment in HIV-positive people to HIV itself. However, around
one-ﬁfth of the general population would achieve scores more
than 1 SD below the mean on 2 of 5 NP tests, rising to half on
2 of 10 tests.12,34 ANI in particular may be a misclassiﬁcation
of those individuals who merely represent 1 end of the normal
population distribution. A recent analysis of data from a gen-
eral population sample in Kenya has estimated that the Fras-
cati criteria may result in a false-positive HAND classiﬁcation
of up to 74% of HIV-positive participants.35
Regarding our neuropsychological testing methodology,
the sensitivity of CogState for detecting impairment across the
full range of abilities and HAND classiﬁcations in HIV-positive
patients is not known. These may be limitations to our
methods, but one should note that CogState is based on
traditional neuropsychological testing methods and has been
used to assess cognitive function across many different
conditions in clinical and nonclinical settings.18–25 Our conclu-
sions warrant replication using other tests of the same cognitive
domains in other samples. We used 2 approaches to measuring
executive function: semantic ﬂuency and a visual maze–based
learning task. Iudicello et al36 have shown that HIV predomi-
nantly affects the executive components of semantic ﬂuency
tasks, that is, the cognitive operations related to switching sets,
rather than any impairment in semantic memory stores. As with
all neuropsychological testing, poor performance observed in
some individuals may reﬂect impairment in cognitive domains
other than that for which the test was intended.
Much of the prevalent NCI in HIV-positive populations
could be caused by factors other than HIV. For example, drug
and alcohol use were high in both HIV-positive and HIV-
negative MSM who took part in this study, and such ﬁndings are
not atypical of HIV-positive populations in many regions.37–39
TABLE 4. Age- and Education-Adjusted Neuropsychological Test Scores in HIV-Positive and HIV-Negative Participants
HIV-Positive MSM (N = 251)* HIV-Negative MSM (N = 45) P Favors Group
Detection latency, mean (SD) log10 ms 2.53 (0.14) 2.56 (0.12) 0.091 HIV positive
Identiﬁcation latency, mean (SD) log10 ms 2.71 (0.12) 2.75 (0.10) 0.0057 HIV positive
Groton Maze learning, mean (SD) No. errors 48.1 (24.3) 49.3 (19.9) 0.70 HIV positive
Groton Maze recall, mean (SD) No. errors 7.18 (6.3) 7.15 (5.2) 0.98 HIV negative
One-back accuracy, mean (SD) arcsine-transformed
proportion correct
1.36 (0.22) 1.38 (0.18) 0.54 HIV negative
One-back latency, mean (SD) log10 ms 2.85 (0.14) 2.87 (0.12) 0.29 HIV positive
Shopping list learning, mean (SD) No. correct
responses†
26.3 (6.1) 26.1 (4.9) 0.77 HIV positive
Shopping list recall, mean (SD) No. correct responses† 8.7 (3.3) 8.6 (2.6) 0.73 HIV positive
COWAT, mean (SD) No. valid responses*† 41.4 (17.6) 43.5 (14.1) 0.30 HIV negative
CFT, mean (SD) No. valid responses*† 22.5 (9.0) 21.3 (7.2) 0.26 HIV positive
*Three HIV-positive participants had no data for the COWAT or CFT.
†Results for verbal tasks were also adjusted for ﬂuency in English.
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Mental health conditions, poor premorbid educational attainment,
suboptimal effort by participants, and culturally inappropriate
tests or norms may all lead to underestimates of NP function.
This raises some important clinical and ethical concerns. First,
HIV management decisions, such as altering an ART regimen on
the basis of a diagnosis of HAND, are questionable, and other
factors should be considered and addressed. Second, the diagno-
sis of ANI could be potentially distressing for HIV-positive in-
dividuals, and neuropsychological labels in general may have
negative effects and should be applied with caution especially
when the prognosis and impact are uncertain.
We found higher rates of self-reported attribution of
functional impairment to cognitive difﬁculties in the HIV-
positive group compared with the HIV-negative group (18.8%
vs. 6.6%). This suggests that HIV-positive patients are already
more vigilant to possible NCI symptoms, perhaps resulting
from knowledge of high published prevalence rates. Another
possible explanation may be that the study’s opportunistic sam-
pling strategy led to over-recruitment of patients with particular
concerns about their neuropsychological health.
Estimates of NCI prevalence in HIV-positive samples
also depend on the characteristics of the reference population
from whom norms are derived. Choice of reference data can
signiﬁcantly affect overall rates of neuropsychological abnor-
mality, in some cases quadrupling it.40 It is important to use
a suitable control population, and lack of appropriate methods
to control for education, lifestyle, and behavioral character-
istics is a limitation of previous studies.41 Our control group
was small, which limits our ability to compare neurocognitive
function between the 2 groups. We were able to adjust our
analyses for age and education, the most important confound-
ers. Substance misuse and mental health problems were com-
mon in both HIV-positive and negative groups, but there may
have been other unrecognized confounders in our sample.
Education is an important protective factor for dementia
in the general population. It is theorized that “cognitive
reserve”42 may compensate for neurodegeneration and aging
and thus afford preservation of neuropsychological function
in the face of these effects.43 Both groups of MSM in our
study had relatively high levels of education and may have
had greater cognitive reserve, which is also potentially pro-
tective against the neurological effects of HIV.44
In summary, these ﬁndings have implications for
classifying NCI, show that levels of NCI in HIV-positive
MSM in the United Kingdom could have been overestimated,
and suggest that diagnosed deﬁcits may often not be related to
HIV. We propose a re-evaluation of current diagnostic criteria
for NCI in HIV, for example, by increasing the level of deﬁcit
required to meet the criteria, improving the validity of assess-
ments of everyday function, standardizing NP assessment
procedures or weighting particular cognitive domains, includ-
ing biomarkers, or incorporating repeat assessments. We also
propose that the cognitive health of HIV-positive patients
should be protected by addressing factors associated with
cognitive dysfunction in the general population, for example,
by promoting regular exercise and smoking cessation, reducing
alcohol and recreational drug use, increasing fruit and
vegetable consumption, and treating diabetes and depression.43
When interpreting estimates of HAND prevalence, it is
important to recognize our inability to speciﬁcally attribute
NCI to HIV infection, the inadequacy of imaging and biochem-
ical markers except in severe cases,45,46 issues with the neuro-
psychological tests themselves, and the confounding effects of
age, education, and culture. Only through correct classiﬁcation
we can maximize the efﬁcacy of recommended interventions in
those with true HIV-related cognitive impairment.
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